152 related articles for article (PubMed ID: 8679270)
1. Targeted radiotherapy of osteosarcoma using 153 Sm-EDTMP. A new promising approach.
Bruland OS; Skretting A; Solheim OP; Aas M
Acta Oncol; 1996; 35(3):381-4. PubMed ID: 8679270
[TBL] [Abstract][Full Text] [Related]
2. High-dose samarium-153 ethylene diamine tetramethylene phosphonate: low toxicity of skeletal irradiation in patients with osteosarcoma and bone metastases.
Anderson PM; Wiseman GA; Dispenzieri A; Arndt CA; Hartmann LC; Smithson WA; Mullan BP; Bruland OS
J Clin Oncol; 2002 Jan; 20(1):189-96. PubMed ID: 11773169
[TBL] [Abstract][Full Text] [Related]
3. [153Sm-EDTMP for moderate and severe bone cancer pain].
Deng H; Luo S; Tan T; Mo T; Liang Z; Pu M; Jiao J; Zhong S; Wang Q; Hu Y
Hua Xi Yi Ke Da Xue Xue Bao; 1995 Dec; 26(4):391-4. PubMed ID: 8732058
[TBL] [Abstract][Full Text] [Related]
4. High-activity samarium-153-EDTMP therapy in unresectable osteosarcoma.
Franzius C; Bielack S; Sciuk J; Vollet B; Jürgens H; Schober O
Nuklearmedizin; 1999; 38(8):337-40. PubMed ID: 10615669
[TBL] [Abstract][Full Text] [Related]
5. Samarium lexidronam (153Sm-EDTMP): skeletal radiation for osteoblastic bone metastases and osteosarcoma.
Anderson P; Nuñez R
Expert Rev Anticancer Ther; 2007 Nov; 7(11):1517-27. PubMed ID: 18020921
[TBL] [Abstract][Full Text] [Related]
6. Targeted radiotherapy with Sm-153-EDTMP in nine cases of canine primary bone tumours.
Milner RJ; Dormehl I; Louw WK; Croft S
J S Afr Vet Assoc; 1998 Mar; 69(1):12-7. PubMed ID: 9646255
[TBL] [Abstract][Full Text] [Related]
7. [Primary investigation of dose-effect relationship of 153Sm-EDTMP in treating multiple bone metastases].
Fan W; Chen LX; Liu XW; Tang Q; Wang GH; Zhi SF; Zeng ZY
Ai Zheng; 2006 Nov; 25(11):1395-8. PubMed ID: 17094908
[TBL] [Abstract][Full Text] [Related]
8. Prospective evaluation of samarium-153-EDTMP radionuclide treatment for bone metastases in patients with hormone-refractory prostate cancer.
Dolezal J; Vizda J; Odrazka K
Urol Int; 2007; 78(1):50-7. PubMed ID: 17192733
[TBL] [Abstract][Full Text] [Related]
9. Systemic metabolic radiotherapy with samarium-153 EDTMP for the treatment of painful bone metastasis.
Serafini AN
Q J Nucl Med; 2001 Mar; 45(1):91-9. PubMed ID: 11456381
[TBL] [Abstract][Full Text] [Related]
10. Combined use of zoledronic acid and 153Sm-EDTMP in hormone-refractory prostate cancer patients with bone metastases.
Lam MG; Dahmane A; Stevens WH; van Rijk PP; de Klerk JM; Zonnenberg BA
Eur J Nucl Med Mol Imaging; 2008 Apr; 35(4):756-65. PubMed ID: 18157530
[TBL] [Abstract][Full Text] [Related]
11. Samarium-153 EDTMP therapy of disseminated skeletal metastasis.
Turner JH; Martindale AA; Sorby P; Hetherington EL; Fleay RF; Hoffman RF; Claringbold PG
Eur J Nucl Med; 1989; 15(12):784-95. PubMed ID: 2483138
[TBL] [Abstract][Full Text] [Related]
12. Samarium-153-EDTMP in bone metastases.
Ahonen A; Joensuu H; Hiltunen J; Hannelin M; Heikkilä J; Jakobsson M; Jurvelin J; Kairemo K; Kumpulainen E; Kulmala J
J Nucl Biol Med (1991); 1994 Dec; 38(4 Suppl 1):123-7. PubMed ID: 7543288
[TBL] [Abstract][Full Text] [Related]
13. Samarium-153-labelled EDTMP for bone metastases from cancer of the prostate.
Sandeman TF; Budd RS; Martin JJ
Clin Oncol (R Coll Radiol); 1992 May; 4(3):160-4. PubMed ID: 1375094
[TBL] [Abstract][Full Text] [Related]
14. Treatment of bone pain secondary to metastases using samarium-153-EDTMP.
Etchebehere EC; Pereira Neto CA; Lima MC; Santos Ade O; Ramos CD; Silva CM; Camargo EE
Sao Paulo Med J; 2004 Sep; 122(5):208-12. PubMed ID: 15558143
[TBL] [Abstract][Full Text] [Related]
15. Samarium for osteoblastic bone metastases and osteosarcoma.
Anderson P
Expert Opin Pharmacother; 2006 Aug; 7(11):1475-86. PubMed ID: 16859431
[TBL] [Abstract][Full Text] [Related]
16. Multicentre trial on the efficacy and toxicity of single-dose samarium-153-ethylene diamine tetramethylene phosphonate as a palliative treatment for painful skeletal metastases in China.
Tian JH; Zhang JM; Hou QT; Oyang QH; Wang JM; Luan ZS; Chuan L; He YJ
Eur J Nucl Med; 1999 Jan; 26(1):2-7. PubMed ID: 9933654
[TBL] [Abstract][Full Text] [Related]
17. Palliation of pain associated with metastatic bone cancer using samarium-153 lexidronam: a double-blind placebo-controlled clinical trial.
Serafini AN; Houston SJ; Resche I; Quick DP; Grund FM; Ell PJ; Bertrand A; Ahmann FR; Orihuela E; Reid RH; Lerski RA; Collier BD; McKillop JH; Purnell GL; Pecking AP; Thomas FD; Harrison KA
J Clin Oncol; 1998 Apr; 16(4):1574-81. PubMed ID: 9552068
[TBL] [Abstract][Full Text] [Related]
18. ESR dosimetry of 89Sr and 153Sm in bone.
Kinoshita A; Braga FJ; Graeff CF; Baffa O
Appl Radiat Isot; 2001 Feb; 54(2):269-74. PubMed ID: 11200888
[TBL] [Abstract][Full Text] [Related]
19. [Myelotoxicity after systemic radionuclide therapy of painful bone metastases with 153Samarium-EDTMP ].
Dolezal J; Vizd'a J; Cermáková E
Vnitr Lek; 2003 Mar; 49(3):189-93. PubMed ID: 12728593
[TBL] [Abstract][Full Text] [Related]
20. A dose-controlled study of 153Sm-ethylenediaminetetramethylenephosphonate (EDTMP) in the treatment of patients with painful bone metastases.
Resche I; Chatal JF; Pecking A; Ell P; Duchesne G; Rubens R; Fogelman I; Houston S; Fauser A; Fischer M; Wilkins D
Eur J Cancer; 1997 Sep; 33(10):1583-91. PubMed ID: 9389919
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
